Trials / Terminated
TerminatedNCT02939599
Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
Long-term, Open Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of QCC374 in Patients With Pulmonary Arterial Hypertension (PAH)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a long-term open-label safety extension to the Phase 2a study of inhaled QCC374 in adult patients with PAH. This study provides the patients who completed the QCC374X2201 study with the option to continue receiving QCC374. The study will monitor the long-term safety, tolerability and efficacy of QCC374 in patients with PAH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QCC374 | 0.015mg and 0.06mg |
Timeline
- Start date
- 2018-02-01
- Primary completion
- 2018-11-06
- Completion
- 2018-11-06
- First posted
- 2016-10-20
- Last updated
- 2021-01-05
- Results posted
- 2020-02-28
Locations
4 sites across 3 countries: United States, Germany, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02939599. Inclusion in this directory is not an endorsement.